Coloplast has launched a randomized, cross-over trial of Heylo, which is a supporting ostomy product designed to detect leakages, according to a filing on Thursday on database Clinical Trials, which collects information about clinical studies.
Heylo is an add-on sensor layer, which is placed underneath the baseplate of the ostomy to detect moisture and leakages. A transmitter sends a notification to an app, alerting the user of any potential problems.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.